Literature DB >> 31602367

Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2019        PMID： 31602367      PMCID： PMC6738201          DOI： 10.1159/000501501

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  29 in total

Review 1.  Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2017-02-02       Impact factor: 2.935

2.  Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.

Authors:  Haruhiko Yoshida; Yasushi Shiratori; Masatoshi Kudo; Shuichiro Shiina; Toshihiko Mizuta; Masamichi Kojiro; Kyosuke Yamamoto; Yukihiro Koike; Kenichi Saito; Nozomu Koyanagi; Takao Kawabe; Seiji Kawazoe; Haruhiko Kobashi; Hiroshi Kasugai; Yukio Osaki; Yasuyuki Araki; Namiki Izumi; Hiroko Oka; Kunihiko Tsuji; Joji Toyota; Toshihito Seki; Toshiya Osawa; Naohiko Masaki; Masao Ichinose; Masataka Seike; Akihisa Ishikawa; Yoshiyuki Ueno; Kazumi Tagawa; Ryoko Kuromatsu; Shotaro Sakisaka; Hiroshi Ikeda; Hidekatsu Kuroda; Hiroyuki Kokuryu; Tatsuya Yamashita; Isao Sakaida; Tetsuo Katamoto; Kentaro Kikuchi; Minoru Nomoto; Masao Omata
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Authors:  Austin G Duffy; Susanna V Ulahannan; Oxana Makorova-Rusher; Osama Rahma; Heiner Wedemeyer; Drew Pratt; Jeremy L Davis; Marybeth S Hughes; Theo Heller; Mei ElGindi; Ashish Uppala; Firouzeh Korangy; David E Kleiner; William D Figg; David Venzon; Seth M Steinberg; Aradhana M Venkatesan; Venkatesh Krishnasamy; Nadine Abi-Jaoudeh; Elliot Levy; Brad J Wood; Tim F Greten
Journal:  J Hepatol       Date:  2016-11-02       Impact factor: 25.083

4.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

6.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M Llovet
Journal:  Lancet Oncol       Date:  2015-09-08       Impact factor: 41.316

7.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

8.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

9.  Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence.

Authors:  Chiara Carone; Andrea Olivani; Raffaele Dalla Valle; Roberta Manuguerra; Enrico Maria Silini; Tommaso Trenti; Gabriele Missale; Elisabetta Cariani
Journal:  Liver Cancer       Date:  2018-03-06       Impact factor: 11.740

10.  Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.

Authors:  Kiwamu Okita; Namiki Izumi; Osamu Matsui; Katsuaki Tanaka; Shuichi Kaneko; Hisataka Moriwaki; Kenji Ikeda; Yukio Osaki; Kazushi Numata; Kohei Nakachi; Norihiro Kokudo; Kazuho Imanaka; Shuhei Nishiguchi; Takuji Okusaka; Yoichi Nishigaki; Susumu Shiomi; Masatoshi Kudo; Kenichi Ido; Yoshiyasu Karino; Norio Hayashi; Yasuo Ohashi; Masatoshi Makuuchi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2014-04-13       Impact factor: 7.527
View more
  21 in total

1.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

2.  Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-15       Impact factor: 11.740

3.  Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.

Authors:  Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

4.  Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-27       Impact factor: 11.740

5.  Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.

Authors:  Tomoko Aoki; Naoshi Nishida; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Akira Yamada; Keitaro Sofue; Masakatsu Tsurusaki; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-08-19       Impact factor: 11.740

6.  Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.

Authors:  Qingyun Yuan; Qiaoyan Liang; Zujun Sun; Xingxing Yuan; Weihua Hou; Yuxiong Wang; Huijie Wang; Min Yu
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

Review 7.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

Review 8.  Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

Review 9.  Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.

Authors:  Christoph Roderburg; Burcin Özdirik; Alexander Wree; Münevver Demir; Frank Tacke
Journal:  Hepat Oncol       Date:  2020-05-28

Review 10.  Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Joji Tani; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.